Toinv,

I definately like your thinking , if you do the  research you will see a large equity financing in RVX about 8 years ago was completed by NGN capital. Peter Johann a general partner with NGN has a  very good relationship and was the former head of Corporate development with Boehringer Ingelheim so between both Peter Johann and Chris Boehringer and Peter being on RVX board  they may have an upper hand in the trial knowledge to pass on to BI for a possible deal, you  never know but if the trial results are good, I think will ahvea lot of pharma's fighting over deals for either a buyout or partnership